ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
The Avanzar study could read out shortly.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
The company reckons its immunotherapy could improve on Keytruda.
